RT Journal Article
T1 Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
A1 Capdevila, Jaume
A1 Sevilla, Isabel
A1 Alonso, Vicente
A1 Antón Aparicio, Luís
A1 Jiménez Fonseca, Paula
A1 Grande, Enrique
A1 Reina, Juan José
A1 Manzano, José Luís
A1 Alonso Lájara, Juan Domingo
A1 Barriuso, Jorge
A1 Castellano, Daniel
A1 Medina, Javier
A1 López, Carlos
A1 Segura, Ángel
A1 Carrera, Sergio
A1 Crespo, Guillermo
A1 Fuster, José
A1 Munarriz, Javier
A1 García Alfonso, Pilar
K1 Lanreotide
K1 Neuroendocrine tumours
K1 Sunitinib
K1 Everolimus
K1 Somatostatin analogues
K1 Clinical practice
K1 Cross-sectional analysis
K1 Combination treatment
K1 Tumores Neuroendocrinos
K1 Péptidos Cíclicos
K1 Estudios Prospectivos
K1 Sirolimus
K1 Somatostatina
K1 Inhibidores de la Angiogénesis
AB BACKGROUNDBased on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). Herein, we investigate the use of these treatment combinations in clinical practice.METHODSThis retrospective cross-sectional analysis of patients with NETs treated with the SSA lanreotide and targeted therapies at 35 Spanish hospitals evaluated the efficacy and safety of lanreotide treatment combinations in clinical practice. The data of 159 treatment combinations with lanreotide in 133 patients was retrospectively collected.RESULTSOf the 133 patients, with a median age of 59.4 (16-83) years, 70 (52.6 %) patients were male, 64 (48.1 %) had pancreatic NET, 23 (17.3 %) had ECOG PS ≥2, 41 (30.8 %) had functioning tumours, 63 (47.7 %) underwent surgery of the primary tumour, 45 (33.8 %) had received prior chemotherapy, and 115 (86.5 %) had received prior SSAs. 115 patients received 1 lanreotide treatment combination and 18 patients received between 2 and 5 combinations. Lanreotide was mainly administered in combination with everolimus (73 combinations) or sunitinib (61 combinations). The probability of being progression-free was 78.5 % (6 months), 68.6 % (12 months) and 57.0 % (18 months) for patients who only received everolimus plus lanreotide (n = 57) and 89.3 % (6 months), 73.0 % (12 months), and 67.4 % (18 months) for patients who only received sunitinib and lanreotide (n = 50). In patients who only received everolimus plus lanreotide the median time-to-progression from the initiation of lanreotide combination treatment was 25.8 months (95 % CI, 11.3, 40.3) and it had not yet been reached among the subgroup of patients only receiving sunitinib plus lanreotide. The safety profile of the combination treatment was comparable to that of the targeted agent alone.CONCLUSIONSThe combination of lanreotide and targeted therapies, mainly everolimus and sunitinib, is widely used in clinical practice without unexpected toxicities and suggests efficacy that should be explored in randomized prospective clinical trials.
PB BioMed Central
YR 2015
FD 2015-07-04
LK http://hdl.handle.net/10668/1984
UL http://hdl.handle.net/10668/1984
LA en
NO Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015; 15:495
NO Journal Article;
DS RISalud
RD Apr 6, 2025